Is TB-500 Legal in Colorado? How to Access It Legally

HealthRX.com

Federal status is clear; Colorado law is not covered here

Print or save as PDF

See the public record for TB-500

  • FDA approval / None in the US or in the other countries FDA checked [1]
  • FDA compounding lists / Not on the pharmacy list or the outsourcing-facility list [2][3][4]
  • FDA staff position / Recommended against adding it, July 2026 [1]
  • Advisory committee / Voted in favor July 23, 2026; advice only [7][5]
  • HHS / October 2026 draft enforcement discretion for TB-500 acetate by injection; not an approval [5][6]
  • Sport / Prohibited at all times by WADA, S2.3 [8][9]

What TB-500 is

TB-500 is a synthetic 7-amino-acid, N-acetylated fragment (residues 17 to 23, about 889 g/mol) of the 43-amino-acid protein thymosin beta-4; it is not the full-length protein and not thymosin alpha-1 [1]. 'TB-500' is a common name, and FDA found several salts and derivatives, some with different active moieties, sold under it [1]. It is sold online as research-use-only injectable powder in 2 mg to 15 mg vials, alone or blended with BPC-157 [1].

Where it stands with FDA

No FDA-approved drug contains TB-500 [1]. FDA's July 2026 review found no USP or National Formulary monograph, no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, and none authorized by the European Medicines Agency [1].

Under the compounding framework FDA describes, a state-licensed pharmacy may use a bulk substance only if it has a USP or NF monograph, is a component of an FDA-approved drug, or appears on FDA's bulks list [4]. TB-500 meets none of those, and it appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians or on the list for outsourcing facilities [1][2][3][4].

FDA staff proposed in July 2026 that neither TB-500 free base nor TB-500 acetate be added to the list, citing inconsistent naming, missing impurity and endotoxin data, unclear historical use, no evidence of effectiveness for wound healing, no human data, and immunogenicity risk for an injectable [1]. The Pharmacy Compounding Advisory Committee voted in favor of adding it on July 23, 2026, against that recommendation; the vote is advice only, TB-500 is not on the list, and adding it takes rulemaking [7][5].

The HHS draft policy

HHS filed a draft enforcement-discretion policy on October 28, 2026 (Federal Register document 2026-22192), naming TB-500 among six peptides and covering the acetate form given by subcutaneous or intramuscular injection [5][6]. HHS says it does not intend to take enforcement action against a state-licensed pharmacy, federal facility or licensed physician compounding with it if conditions are met, such as a single active ingredient, a patient-specific prescription, and an FDA-registered manufacturer with a certificate of analysis [5][6]. The notice states that it establishes no rights, is not binding on HHS or the public, and may be revisited [5]. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before marketing [5].

Safety and dosing

FDA found no nonclinical toxicity studies, no immunogenicity data, and no published article in which TB-500 was given to a human; its adverse-event database search through March 26, 2025 retrieved no TB-500 reports [1]. Its food and supplement complaint system returned two cases about a blended TB-500 and BPC-157 product with no safety assessment [1]. The stated concern for an injectable is immunogenicity, potentially amplified by aggregation and peptide-related impurities [1].

There is no approved TB-500 dose, and FDA found no human dosing study of TB-500 [1]. FDA reviewed a nomination proposing a 3 mg/mL injectable powder; that concentration is not a tested human dose [1].

Athletes

WADA's Prohibited List names 'Thymosin-beta4 and its derivatives e.g. TB-500' in S2.3, growth factors and growth factor modulators, prohibited at all times in and out of competition, on both the 2026 and 2027 Lists [8][9].

Colorado rules

This page describes federal status only. The federal information does not determine whether Colorado law permits access to TB-500. The HHS draft policy applies to state-licensed pharmacies and licensed physicians compounding injectable TB-500 acetate when its conditions are met [5][6].

Check what you know

Think you have it? Try 3 quick questions and see what the article says.

1. Under the compounding framework FDA describes, which is one condition for a state-licensed pharmacy to use a bulk substance?

Question 1 of 3

Score: 0 right, 0 of 3 answered

Questions worth asking

Choose the questions you want to keep

Is TB-500 legal in Colorado?
Federally, it is not FDA-approved and appears in none of the categories on FDA's compounding lists [1][2][3][4]. This page does not address Colorado-specific law. A draft HHS policy describes conditional enforcement discretion for compounding injectable TB-500 acetate [5][6].
Can a Colorado pharmacy compound TB-500?
A state-licensed pharmacy may use a bulk substance only with a USP or NF monograph, as a component of an FDA-approved drug, or from FDA's bulks list [4]. TB-500 meets none of those conditions [1][2][3][4].
Did the July 2026 advisory committee vote make TB-500 legal?
No. The committee voted in favor of adding it on July 23, 2026, but that advice is not binding, TB-500 is not on the list, and adding it requires rulemaking [7][5].
Has TB-500 been tested in people?
FDA found no published article in which TB-500 was given to a human, and there is no approved dose [1].
Is TB-500 banned in sport?
Yes. WADA lists thymosin-beta-4 and its derivatives including TB-500 in S2.3, prohibited at all times [8][9].
Show all 9 referencesHide references
Evidence overview for Is TB-500 Legal in Colorado? How to Access It Legally